Sanofi Revenue 2006-2018 | SNY

Sanofi annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Sanofi revenue for the quarter ending June 30, 2018 was $0.000B, a 100% decline year-over-year.
  • Sanofi revenue for the twelve months ending June 30, 2018 was $31.600B, a 20.17% decline year-over-year.
  • Sanofi annual revenue for 2018 was $42.135B, a 2.96% increase from 2017.
  • Sanofi annual revenue for 2017 was $40.921B, a 6.54% increase from 2016.
  • Sanofi annual revenue for 2016 was $38.408B, a 0.78% decline from 2015.
Sanofi Annual Revenue
(Millions of US $)
2018 $42,135
2017 $40,921
2016 $38,408
2015 $38,710
2014 $45,341
2013 $44,240
2012 $46,244
2011 $48,829
2010 $42,539
2009 $42,883
2008 $42,398
2007 $40,034
2006 $37,044
2005 $35,510
Sanofi Quarterly Revenue
(Millions of US $)
Q2 2018 $0
Q1 2018 $9,988
Q4 2017 $10,572
Q3 2017 $11,040
Q2 2017 $9,828
Q1 2017 $9,482
Q4 2016 $9,904
Q3 2016 $10,373
Q2 2016 $9,385
Q1 2016 $8,746
Q3 2015 $10,770
Q2 2015 $10,466
Q2 2014 $11,175
Q2 2013 $10,560
Q2 2012 $11,716
Q1 2012 $11,247
Q4 2011 $11,701
Q3 2011 $12,087
Q2 2011 $12,061
Q1 2011 $11,423
Q4 2010 $10,075
Q3 2010 $10,788
Q2 2010 $10,648
Q1 2010 $9,748
Q4 2009 $10,098
Q3 2009 $10,922
Q2 2009 $10,582
Q1 2009 $9,190
Q4 2008 $9,834
Q3 2008 $10,127
Q2 2008 $10,407
Q1 2008 $10,519
Q4 2007 $10,366
Q3 2007 $10,133
Q2 2007 $9,356
Q1 2007 $9,737
Q4 2006 $9,489
Q3 2006 $8,848
Q2 2006 $8,897
Q1 2006 $8,463
Q4 2005 $8,342
Q3 2005 $8,784
Q2 2005 $8,430
Q1 2005 $8,419
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $111.008B $40.701B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $367.316B 16.74
Pfizer (PFE) United States $249.127B 13.95
Merck (MRK) United States $221.869B 18.96
Novartis AG (NVS) Switzerland $215.800B 18.35
Eli Lilly (LLY) United States $132.844B 23.08
Novo Nordisk (NVO) Denmark $123.936B 20.05
AbbVie (ABBV) United States $117.653B 10.08
AstraZeneca (AZN) United Kingdom $107.876B 12.31
GlaxoSmithKline (GSK) United Kingdom $102.325B 13.44
Bristol-Myers Squibb (BMY) United States $78.630B 12.10